Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 225 participants.
Also called NCT05281549
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 225 participants
- Sponsor
- Registry
-
NCT05281549
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Unknown status
Technical summary
Registry record NCT05281549. Randomized; single masking; primary purpose treatment. Start 2021-05-02 (actual); primary completion 2022-01-28 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Thrombolysis Treated With TNK-tPA in Acute Ischemic Stroke Patients (3T Stroke-II)
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Alteplase
- Intervention (Drug)
- Tenecteplase
- Intervention (Drug)
- Tenecteplase
- Lead sponsor
- Beijing Tiantan Hospital
- Collaborator
- Jiangsu FENG HUA Biotech Pharmaceutical Co., Ltd
- Collaborator
- The Place Pharmaceutical(Jiangsu) Co., Ltd
Record details
- Record id
cardio:ct-nct05281549- Content hash
714699792cd5c5fe639f4202013d99d146a8580a18890a7d14443f7531a6bbbb